Cooperativity between miR-125b and Gata1 s in the pathogenesis of Down syndrome-associated myeloid leukemia

2019 ◽  
Author(s):  
O Alejo-Valle ◽  
M Labuhn ◽  
E Emmrich ◽  
M Ng ◽  
D Heckl ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Myeloid Leukemia

scholarly journals Minimally differentiated acute myeloid leukemia with ring/marker derived from chromosome 7 in a child with Down syndrome

2019 ◽  
Vol 41 (1) ◽  
pp. 84-87
Author(s):  
Maria Luiza Rocha da Rosa Borges ◽  
Eliane Maria Soares-Ventura ◽  
Thomas Liehr ◽  
Terezinha de Jesus Marques-Salles
Keyword(s):  
Acute Myeloid Leukemia ◽  
Down Syndrome ◽  
Myeloid Leukemia ◽  
Chromosome 7 ◽  
Acute Myeloid

scholarly journals Infections in children with down syndrome and acute myeloid leukemia: a report from the Canadian infections in AML research group

2013 ◽  
Vol 8 (1) ◽  
pp. 47 ◽  
Author(s):  
Thai Tran ◽  
David Mitchell ◽  
David Dix ◽  
Sonia Cellot ◽  
Marie-Chantal Ethier ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Down Syndrome ◽  
Research Group ◽  
Myeloid Leukemia ◽  
Children With Down Syndrome ◽  
Acute Myeloid

scholarly journals Retrospective Analysis of the Treatment Outcome in Myeloid Leukemia of Down Syndrome in Polish Pediatric Leukemia and Lymphoma Study Group From 2005 to 2019

2020 ◽  
Vol 8 ◽  
Author(s):  
Malgorzata Czogala ◽  
Katarzyna Pawinska-Wasikowska ◽  
Teofila Ksiazek ◽  
Barbara Sikorska-Fic ◽  
Michal Matysiak ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Treatment Outcome ◽  
Retrospective Analysis ◽  
Myeloid Leukemia ◽  
Study Group ◽  
Pediatric Leukemia ◽  
Lymphoma Study Group

scholarly journals Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial

Blood ◽  
2017 ◽  
Vol 129 (25) ◽  
pp. 3314-3321 ◽  
Author(s):  
Madita Uffmann ◽  
Mareike Rasche ◽  
Martin Zimmermann ◽  
Christine von Neuhoff ◽  
Ursula Creutzig ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Prognostic Factors ◽  
Treatment Response ◽  
Early Treatment ◽  
Myeloid Leukemia ◽  
Chromosome 8 ◽  
Historical Control ◽  
Early Treatment Response ◽  
Key Points ◽  
Therapy Reduction

Key Points Reducing therapy intensity in the ML-DS 2006 trial did not impair the excellent prognosis in ML-DS compared with the historical control. Early treatment response and gain of chromosome 8 are independent prognostic factors.

scholarly journals Looking up for AML in Down syndrome

Blood ◽  
2017 ◽  
Vol 129 (25) ◽  
pp. 3273-3274
Author(s):  
Jessica C. Shand
Keyword(s):  
Down Syndrome ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Prospective Trial ◽  
Prognostic Significance ◽  
Oncology Group ◽  
Reduced Intensity

In this issue of Blood, Taub et al report improved survival with reduced-intensity therapy and the prognostic significance of end-induction residual disease from the largest prospective trial to date in children with myeloid leukemia of Down syndrome (ML-DS): the Children’s Oncology Group AAML0431 study.1

scholarly journals Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML

Leukemia ◽  
2007 ◽  
Vol 22 (7) ◽  
pp. 1428-1430 ◽  
Author(s):  
H Hasle ◽  
J Abrahamsson ◽  
M Arola ◽  
A Karow ◽  
A O'Marcaigh ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Myeloid Leukemia ◽  
Leukemia In Children ◽  
Gata1 Mutation ◽  
Risk Of Relapse
Sign in / Sign up

Export Citation Format

Share Document